nodes	percent_of_prediction	percent_of_DWPC	metapath
Propafenone—CYP2C8—Tazarotene—psoriasis	0.0762	0.112	CbGbCtD
Propafenone—CYP1A2—Clobetasol propionate—psoriasis	0.0723	0.107	CbGbCtD
Propafenone—CYP1A2—Methoxsalen—psoriasis	0.038	0.0561	CbGbCtD
Propafenone—CYP2D6—Hydroxyurea—psoriasis	0.0342	0.0505	CbGbCtD
Propafenone—CYP2C8—Cholecalciferol—psoriasis	0.0325	0.048	CbGbCtD
Propafenone—CYP2C8—Mycophenolate mofetil—psoriasis	0.0282	0.0416	CbGbCtD
Propafenone—CYP3A4—Calcitriol—psoriasis	0.0256	0.0378	CbGbCtD
Propafenone—CYP2C9—Cholecalciferol—psoriasis	0.0227	0.0335	CbGbCtD
Propafenone—CYP2C8—Hydrocortisone—psoriasis	0.0226	0.0334	CbGbCtD
Propafenone—CYP2C8—Cyclosporine—psoriasis	0.0214	0.0315	CbGbCtD
Propafenone—CYP2D6—Cholecalciferol—psoriasis	0.0207	0.0306	CbGbCtD
Propafenone—CYP3A4—Methoxsalen—psoriasis	0.0199	0.0294	CbGbCtD
Propafenone—ABCB1—Mycophenolate mofetil—psoriasis	0.0191	0.0282	CbGbCtD
Propafenone—ABCB1—Betamethasone—psoriasis	0.0164	0.0242	CbGbCtD
Propafenone—ABCB1—Prednisolone—psoriasis	0.0162	0.0238	CbGbCtD
Propafenone—ABCB1—Hydrocortisone—psoriasis	0.0153	0.0226	CbGbCtD
Propafenone—ABCB1—Prednisone—psoriasis	0.0153	0.0225	CbGbCtD
Propafenone—CYP2C9—Cyclosporine—psoriasis	0.0149	0.022	CbGbCtD
Propafenone—ABCB1—Cyclosporine—psoriasis	0.0145	0.0213	CbGbCtD
Propafenone—CYP2C8—Dexamethasone—psoriasis	0.0141	0.0208	CbGbCtD
Propafenone—CYP2D6—Cyclosporine—psoriasis	0.0136	0.0201	CbGbCtD
Propafenone—CYP3A4—Cholecalciferol—psoriasis	0.0132	0.0195	CbGbCtD
Propafenone—CYP3A4—Triamcinolone—psoriasis	0.0114	0.0169	CbGbCtD
Propafenone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0114	0.0169	CbGbCtD
Propafenone—CYP2C9—Dexamethasone—psoriasis	0.00981	0.0145	CbGbCtD
Propafenone—CYP3A4—Betamethasone—psoriasis	0.00981	0.0145	CbGbCtD
Propafenone—CYP3A4—Prednisolone—psoriasis	0.00968	0.0143	CbGbCtD
Propafenone—ABCB1—Dexamethasone—psoriasis	0.00952	0.0141	CbGbCtD
Propafenone—CYP3A4—Hydrocortisone—psoriasis	0.00917	0.0135	CbGbCtD
Propafenone—CYP3A4—Prednisone—psoriasis	0.00914	0.0135	CbGbCtD
Propafenone—CYP2D6—Dexamethasone—psoriasis	0.00897	0.0132	CbGbCtD
Propafenone—CYP3A4—Cyclosporine—psoriasis	0.00866	0.0128	CbGbCtD
Propafenone—ABCB1—Methotrexate—psoriasis	0.00765	0.0113	CbGbCtD
Propafenone—CYP3A4—Dexamethasone—psoriasis	0.00571	0.00842	CbGbCtD
Propafenone—Quinapril—ACE—psoriasis	0.00107	0.373	CrCbGaD
Propafenone—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00102	0.0629	CbGpPWpGaD
Propafenone—Benazepril—ACE—psoriasis	0.00093	0.325	CrCbGaD
Propafenone—Carvedilol—VEGFA—psoriasis	0.000865	0.302	CrCbGaD
Propafenone—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000837	0.0516	CbGpPWpGaD
Propafenone—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00083	0.0512	CbGpPWpGaD
Propafenone—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000781	0.0482	CbGpPWpGaD
Propafenone—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000632	0.039	CbGpPWpGaD
Propafenone—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000519	0.032	CbGpPWpGaD
Propafenone—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000514	0.0317	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—IL22—psoriasis	0.000442	0.0273	CbGpPWpGaD
Propafenone—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000439	0.0271	CbGpPWpGaD
Propafenone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000339	0.0209	CbGpPWpGaD
Propafenone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000262	0.0162	CbGpPWpGaD
Propafenone—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000259	0.016	CbGpPWpGaD
Propafenone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000215	0.0133	CbGpPWpGaD
Propafenone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000214	0.0132	CbGpPWpGaD
Propafenone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000213	0.0131	CbGpPWpGaD
Propafenone—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000213	0.0131	CbGpPWpGaD
Propafenone—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000211	0.013	CbGpPWpGaD
Propafenone—SCN5A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000185	0.0114	CbGpPWpGaD
Propafenone—ADRB1—Melatonin metabolism and effects—APOE—psoriasis	0.000184	0.0113	CbGpPWpGaD
Propafenone—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000183	0.0113	CbGpPWpGaD
Propafenone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000182	0.0113	CbGpPWpGaD
Propafenone—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00018	0.0111	CbGpPWpGaD
Propafenone—KCNH2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000179	0.0111	CbGpPWpGaD
Propafenone—ADRB1—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000178	0.011	CbGpPWpGaD
Propafenone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000175	0.0108	CbGpPWpGaD
Propafenone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000173	0.0107	CbGpPWpGaD
Propafenone—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000148	0.00913	CbGpPWpGaD
Propafenone—SCN5A—SIDS Susceptibility Pathways—IL13—psoriasis	0.000146	0.00901	CbGpPWpGaD
Propafenone—KCNH2—SIDS Susceptibility Pathways—IL13—psoriasis	0.000142	0.00873	CbGpPWpGaD
Propafenone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000141	0.00869	CbGpPWpGaD
Propafenone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000139	0.00857	CbGpPWpGaD
Propafenone—ADRB1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00013	0.008	CbGpPWpGaD
Propafenone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000114	0.00704	CbGpPWpGaD
Propafenone—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000113	0.00697	CbGpPWpGaD
Propafenone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000113	0.00695	CbGpPWpGaD
Propafenone—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000111	0.00688	CbGpPWpGaD
Propafenone—ADRB1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000109	0.00674	CbGpPWpGaD
Propafenone—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000108	0.00669	CbGpPWpGaD
Propafenone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000105	0.00648	CbGpPWpGaD
Propafenone—ADRB1—GPCR ligand binding—HCAR2—psoriasis	9.88e-05	0.00609	CbGpPWpGaD
Propafenone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.81e-05	0.00605	CbGpPWpGaD
Propafenone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	9.27e-05	0.00572	CbGpPWpGaD
Propafenone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	9.19e-05	0.00567	CbGpPWpGaD
Propafenone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	9.15e-05	0.00564	CbGpPWpGaD
Propafenone—SCN5A—SIDS Susceptibility Pathways—IL10—psoriasis	9.13e-05	0.00564	CbGpPWpGaD
Propafenone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	9.07e-05	0.0056	CbGpPWpGaD
Propafenone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	8.99e-05	0.00555	CbGpPWpGaD
Propafenone—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	8.94e-05	0.00552	CbGpPWpGaD
Propafenone—KCNH2—SIDS Susceptibility Pathways—IL10—psoriasis	8.85e-05	0.00546	CbGpPWpGaD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	8.76e-05	0.0054	CbGpPWpGaD
Propafenone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.38e-05	0.00517	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—HLA-C—psoriasis	8.37e-05	0.00516	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—IL13—psoriasis	8.32e-05	0.00513	CbGpPWpGaD
Propafenone—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	8.08e-05	0.00498	CbGpPWpGaD
Propafenone—CYP1A2—Biological oxidations—CYP2S1—psoriasis	7.86e-05	0.00485	CbGpPWpGaD
Propafenone—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	7.75e-05	0.00478	CbGpPWpGaD
Propafenone—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	7.74e-05	0.00477	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—IL17A—psoriasis	7.65e-05	0.00472	CbGpPWpGaD
Propafenone—Myalgia—Dexamethasone—psoriasis	7.62e-05	0.000251	CcSEcCtD
Propafenone—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	7.62e-05	0.0047	CbGpPWpGaD
Propafenone—Abdominal pain—Cyclosporine—psoriasis	7.61e-05	0.000251	CcSEcCtD
Propafenone—Body temperature increased—Cyclosporine—psoriasis	7.61e-05	0.000251	CcSEcCtD
Propafenone—Anxiety—Betamethasone—psoriasis	7.6e-05	0.000251	CcSEcCtD
Propafenone—Anxiety—Dexamethasone—psoriasis	7.6e-05	0.000251	CcSEcCtD
Propafenone—Vomiting—Mycophenolic acid—psoriasis	7.56e-05	0.000249	CcSEcCtD
Propafenone—Discomfort—Betamethasone—psoriasis	7.53e-05	0.000248	CcSEcCtD
Propafenone—Discomfort—Dexamethasone—psoriasis	7.53e-05	0.000248	CcSEcCtD
Propafenone—Dyspepsia—Hydrocortisone—psoriasis	7.53e-05	0.000248	CcSEcCtD
Propafenone—Haemoglobin—Methotrexate—psoriasis	7.52e-05	0.000248	CcSEcCtD
Propafenone—Rash—Mycophenolic acid—psoriasis	7.5e-05	0.000247	CcSEcCtD
Propafenone—Dermatitis—Mycophenolic acid—psoriasis	7.49e-05	0.000247	CcSEcCtD
Propafenone—Pain—Prednisolone—psoriasis	7.49e-05	0.000247	CcSEcCtD
Propafenone—Haemorrhage—Methotrexate—psoriasis	7.49e-05	0.000247	CcSEcCtD
Propafenone—Hepatitis—Methotrexate—psoriasis	7.49e-05	0.000247	CcSEcCtD
Propafenone—Urticaria—Mycophenolate mofetil—psoriasis	7.46e-05	0.000246	CcSEcCtD
Propafenone—Headache—Mycophenolic acid—psoriasis	7.45e-05	0.000246	CcSEcCtD
Propafenone—Decreased appetite—Hydrocortisone—psoriasis	7.44e-05	0.000245	CcSEcCtD
Propafenone—Body temperature increased—Mycophenolate mofetil—psoriasis	7.42e-05	0.000245	CcSEcCtD
Propafenone—Abdominal pain—Mycophenolate mofetil—psoriasis	7.42e-05	0.000245	CcSEcCtD
Propafenone—Urinary tract disorder—Methotrexate—psoriasis	7.39e-05	0.000244	CcSEcCtD
Propafenone—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.38e-05	0.000244	CcSEcCtD
Propafenone—Fatigue—Hydrocortisone—psoriasis	7.37e-05	0.000243	CcSEcCtD
Propafenone—Vision blurred—Prednisone—psoriasis	7.35e-05	0.000242	CcSEcCtD
Propafenone—Urethral disorder—Methotrexate—psoriasis	7.34e-05	0.000242	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.34e-05	0.000242	CcSEcCtD
Propafenone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.32e-05	0.00452	CbGpPWpGaD
Propafenone—Pain—Hydrocortisone—psoriasis	7.31e-05	0.000241	CcSEcCtD
Propafenone—Oedema—Betamethasone—psoriasis	7.31e-05	0.000241	CcSEcCtD
Propafenone—Oedema—Dexamethasone—psoriasis	7.31e-05	0.000241	CcSEcCtD
Propafenone—Insomnia—Triamcinolone—psoriasis	7.28e-05	0.00024	CcSEcCtD
Propafenone—Infection—Dexamethasone—psoriasis	7.26e-05	0.000239	CcSEcCtD
Propafenone—Infection—Betamethasone—psoriasis	7.26e-05	0.000239	CcSEcCtD
Propafenone—Ill-defined disorder—Prednisone—psoriasis	7.24e-05	0.000239	CcSEcCtD
Propafenone—Paraesthesia—Triamcinolone—psoriasis	7.23e-05	0.000239	CcSEcCtD
Propafenone—Feeling abnormal—Prednisolone—psoriasis	7.22e-05	0.000238	CcSEcCtD
Propafenone—Visual impairment—Methotrexate—psoriasis	7.21e-05	0.000238	CcSEcCtD
Propafenone—Anaemia—Prednisone—psoriasis	7.21e-05	0.000238	CcSEcCtD
Propafenone—Shock—Betamethasone—psoriasis	7.19e-05	0.000237	CcSEcCtD
Propafenone—Shock—Dexamethasone—psoriasis	7.19e-05	0.000237	CcSEcCtD
Propafenone—Dyspnoea—Triamcinolone—psoriasis	7.18e-05	0.000237	CcSEcCtD
Propafenone—Nervous system disorder—Betamethasone—psoriasis	7.17e-05	0.000236	CcSEcCtD
Propafenone—Nervous system disorder—Dexamethasone—psoriasis	7.17e-05	0.000236	CcSEcCtD
Propafenone—Thrombocytopenia—Dexamethasone—psoriasis	7.15e-05	0.000236	CcSEcCtD
Propafenone—Thrombocytopenia—Betamethasone—psoriasis	7.15e-05	0.000236	CcSEcCtD
Propafenone—Tachycardia—Betamethasone—psoriasis	7.13e-05	0.000235	CcSEcCtD
Propafenone—Tachycardia—Dexamethasone—psoriasis	7.13e-05	0.000235	CcSEcCtD
Propafenone—ABCB1—Allograft Rejection—IL12B—psoriasis	7.12e-05	0.00439	CbGpPWpGaD
Propafenone—Hypersensitivity—Cyclosporine—psoriasis	7.09e-05	0.000234	CcSEcCtD
Propafenone—Dyspepsia—Triamcinolone—psoriasis	7.09e-05	0.000234	CcSEcCtD
Propafenone—Nausea—Mycophenolic acid—psoriasis	7.07e-05	0.000233	CcSEcCtD
Propafenone—Hyperhidrosis—Dexamethasone—psoriasis	7.06e-05	0.000233	CcSEcCtD
Propafenone—Hyperhidrosis—Betamethasone—psoriasis	7.06e-05	0.000233	CcSEcCtD
Propafenone—Feeling abnormal—Hydrocortisone—psoriasis	7.05e-05	0.000232	CcSEcCtD
Propafenone—Malaise—Prednisone—psoriasis	7.03e-05	0.000232	CcSEcCtD
Propafenone—Vertigo—Prednisone—psoriasis	7.01e-05	0.000231	CcSEcCtD
Propafenone—Eye disorder—Methotrexate—psoriasis	7e-05	0.000231	CcSEcCtD
Propafenone—Gastrointestinal pain—Hydrocortisone—psoriasis	6.99e-05	0.000231	CcSEcCtD
Propafenone—Syncope—Prednisone—psoriasis	6.99e-05	0.000231	CcSEcCtD
Propafenone—Tinnitus—Methotrexate—psoriasis	6.98e-05	0.00023	CcSEcCtD
Propafenone—Anorexia—Dexamethasone—psoriasis	6.97e-05	0.00023	CcSEcCtD
Propafenone—Anorexia—Betamethasone—psoriasis	6.97e-05	0.00023	CcSEcCtD
Propafenone—Urticaria—Prednisolone—psoriasis	6.96e-05	0.000229	CcSEcCtD
Propafenone—Cardiac disorder—Methotrexate—psoriasis	6.95e-05	0.000229	CcSEcCtD
Propafenone—ABCB1—Allograft Rejection—HLA-E—psoriasis	6.95e-05	0.00429	CbGpPWpGaD
Propafenone—Fatigue—Triamcinolone—psoriasis	6.94e-05	0.000229	CcSEcCtD
Propafenone—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.92e-05	0.000228	CcSEcCtD
Propafenone—Asthenia—Cyclosporine—psoriasis	6.91e-05	0.000228	CcSEcCtD
Propafenone—Pain—Triamcinolone—psoriasis	6.89e-05	0.000227	CcSEcCtD
Propafenone—Loss of consciousness—Prednisone—psoriasis	6.85e-05	0.000226	CcSEcCtD
Propafenone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.84e-05	0.00422	CbGpPWpGaD
Propafenone—Hypotension—Betamethasone—psoriasis	6.83e-05	0.000225	CcSEcCtD
Propafenone—Hypotension—Dexamethasone—psoriasis	6.83e-05	0.000225	CcSEcCtD
Propafenone—Pruritus—Cyclosporine—psoriasis	6.81e-05	0.000225	CcSEcCtD
Propafenone—Urticaria—Hydrocortisone—psoriasis	6.79e-05	0.000224	CcSEcCtD
Propafenone—Angiopathy—Methotrexate—psoriasis	6.79e-05	0.000224	CcSEcCtD
Propafenone—CYP1A2—Tryptophan metabolism—CAT—psoriasis	6.78e-05	0.00418	CbGpPWpGaD
Propafenone—Immune system disorder—Methotrexate—psoriasis	6.76e-05	0.000223	CcSEcCtD
Propafenone—Body temperature increased—Hydrocortisone—psoriasis	6.76e-05	0.000223	CcSEcCtD
Propafenone—Abdominal pain—Hydrocortisone—psoriasis	6.76e-05	0.000223	CcSEcCtD
Propafenone—Convulsion—Prednisone—psoriasis	6.76e-05	0.000223	CcSEcCtD
Propafenone—Mediastinal disorder—Methotrexate—psoriasis	6.75e-05	0.000223	CcSEcCtD
Propafenone—Asthenia—Mycophenolate mofetil—psoriasis	6.74e-05	0.000222	CcSEcCtD
Propafenone—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.74e-05	0.00416	CbGpPWpGaD
Propafenone—Hypertension—Prednisone—psoriasis	6.73e-05	0.000222	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Betamethasone—psoriasis	6.66e-05	0.00022	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.66e-05	0.00022	CcSEcCtD
Propafenone—Pruritus—Mycophenolate mofetil—psoriasis	6.64e-05	0.000219	CcSEcCtD
Propafenone—Myalgia—Prednisone—psoriasis	6.64e-05	0.000219	CcSEcCtD
Propafenone—Feeling abnormal—Triamcinolone—psoriasis	6.64e-05	0.000219	CcSEcCtD
Propafenone—Anxiety—Prednisone—psoriasis	6.62e-05	0.000218	CcSEcCtD
Propafenone—Alopecia—Methotrexate—psoriasis	6.62e-05	0.000218	CcSEcCtD
Propafenone—Insomnia—Betamethasone—psoriasis	6.61e-05	0.000218	CcSEcCtD
Propafenone—Insomnia—Dexamethasone—psoriasis	6.61e-05	0.000218	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.59e-05	0.000217	CcSEcCtD
Propafenone—Diarrhoea—Cyclosporine—psoriasis	6.59e-05	0.000217	CcSEcCtD
Propafenone—Paraesthesia—Betamethasone—psoriasis	6.56e-05	0.000216	CcSEcCtD
Propafenone—Paraesthesia—Dexamethasone—psoriasis	6.56e-05	0.000216	CcSEcCtD
Propafenone—Discomfort—Prednisone—psoriasis	6.56e-05	0.000216	CcSEcCtD
Propafenone—Mental disorder—Methotrexate—psoriasis	6.56e-05	0.000216	CcSEcCtD
Propafenone—Malnutrition—Methotrexate—psoriasis	6.52e-05	0.000215	CcSEcCtD
Propafenone—Erythema—Methotrexate—psoriasis	6.52e-05	0.000215	CcSEcCtD
Propafenone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.47e-05	0.00399	CbGpPWpGaD
Propafenone—Hypersensitivity—Prednisolone—psoriasis	6.45e-05	0.000213	CcSEcCtD
Propafenone—Dyspepsia—Betamethasone—psoriasis	6.43e-05	0.000212	CcSEcCtD
Propafenone—Dyspepsia—Dexamethasone—psoriasis	6.43e-05	0.000212	CcSEcCtD
Propafenone—Diarrhoea—Mycophenolate mofetil—psoriasis	6.42e-05	0.000212	CcSEcCtD
Propafenone—Urticaria—Triamcinolone—psoriasis	6.4e-05	0.000211	CcSEcCtD
Propafenone—Dysgeusia—Methotrexate—psoriasis	6.38e-05	0.00021	CcSEcCtD
Propafenone—Body temperature increased—Triamcinolone—psoriasis	6.37e-05	0.00021	CcSEcCtD
Propafenone—Dizziness—Cyclosporine—psoriasis	6.36e-05	0.00021	CcSEcCtD
Propafenone—Oedema—Prednisone—psoriasis	6.36e-05	0.00021	CcSEcCtD
Propafenone—Decreased appetite—Dexamethasone—psoriasis	6.35e-05	0.00021	CcSEcCtD
Propafenone—Decreased appetite—Betamethasone—psoriasis	6.35e-05	0.00021	CcSEcCtD
Propafenone—Infection—Prednisone—psoriasis	6.32e-05	0.000209	CcSEcCtD
Propafenone—Gastrointestinal disorder—Dexamethasone—psoriasis	6.31e-05	0.000208	CcSEcCtD
Propafenone—Gastrointestinal disorder—Betamethasone—psoriasis	6.31e-05	0.000208	CcSEcCtD
Propafenone—Hypersensitivity—Hydrocortisone—psoriasis	6.3e-05	0.000208	CcSEcCtD
Propafenone—Fatigue—Betamethasone—psoriasis	6.3e-05	0.000208	CcSEcCtD
Propafenone—Fatigue—Dexamethasone—psoriasis	6.3e-05	0.000208	CcSEcCtD
Propafenone—Shock—Prednisone—psoriasis	6.26e-05	0.000206	CcSEcCtD
Propafenone—SCN5A—Developmental Biology—CARM1—psoriasis	6.25e-05	0.00386	CbGpPWpGaD
Propafenone—Pain—Betamethasone—psoriasis	6.25e-05	0.000206	CcSEcCtD
Propafenone—Pain—Dexamethasone—psoriasis	6.25e-05	0.000206	CcSEcCtD
Propafenone—Nervous system disorder—Prednisone—psoriasis	6.24e-05	0.000206	CcSEcCtD
Propafenone—Tachycardia—Prednisone—psoriasis	6.21e-05	0.000205	CcSEcCtD
Propafenone—Dizziness—Mycophenolate mofetil—psoriasis	6.21e-05	0.000205	CcSEcCtD
Propafenone—Skin disorder—Prednisone—psoriasis	6.18e-05	0.000204	CcSEcCtD
Propafenone—Hyperhidrosis—Prednisone—psoriasis	6.15e-05	0.000203	CcSEcCtD
Propafenone—Vision blurred—Methotrexate—psoriasis	6.14e-05	0.000203	CcSEcCtD
Propafenone—Asthenia—Hydrocortisone—psoriasis	6.14e-05	0.000202	CcSEcCtD
Propafenone—Vomiting—Cyclosporine—psoriasis	6.12e-05	0.000202	CcSEcCtD
Propafenone—Rash—Cyclosporine—psoriasis	6.07e-05	0.0002	CcSEcCtD
Propafenone—Anorexia—Prednisone—psoriasis	6.07e-05	0.0002	CcSEcCtD
Propafenone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.06e-05	0.00374	CbGpPWpGaD
Propafenone—Dermatitis—Cyclosporine—psoriasis	6.06e-05	0.0002	CcSEcCtD
Propafenone—Pruritus—Hydrocortisone—psoriasis	6.05e-05	0.0002	CcSEcCtD
Propafenone—Ill-defined disorder—Methotrexate—psoriasis	6.05e-05	0.000199	CcSEcCtD
Propafenone—Headache—Cyclosporine—psoriasis	6.03e-05	0.000199	CcSEcCtD
Propafenone—Anaemia—Methotrexate—psoriasis	6.02e-05	0.000199	CcSEcCtD
Propafenone—Feeling abnormal—Betamethasone—psoriasis	6.02e-05	0.000199	CcSEcCtD
Propafenone—Feeling abnormal—Dexamethasone—psoriasis	6.02e-05	0.000199	CcSEcCtD
Propafenone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.98e-05	0.00369	CbGpPWpGaD
Propafenone—Gastrointestinal pain—Dexamethasone—psoriasis	5.98e-05	0.000197	CcSEcCtD
Propafenone—Gastrointestinal pain—Betamethasone—psoriasis	5.98e-05	0.000197	CcSEcCtD
Propafenone—Vomiting—Mycophenolate mofetil—psoriasis	5.97e-05	0.000197	CcSEcCtD
Propafenone—Hypersensitivity—Triamcinolone—psoriasis	5.93e-05	0.000196	CcSEcCtD
Propafenone—Rash—Mycophenolate mofetil—psoriasis	5.92e-05	0.000195	CcSEcCtD
Propafenone—Dermatitis—Mycophenolate mofetil—psoriasis	5.91e-05	0.000195	CcSEcCtD
Propafenone—Headache—Mycophenolate mofetil—psoriasis	5.88e-05	0.000194	CcSEcCtD
Propafenone—Malaise—Methotrexate—psoriasis	5.88e-05	0.000194	CcSEcCtD
Propafenone—Vertigo—Methotrexate—psoriasis	5.85e-05	0.000193	CcSEcCtD
Propafenone—Diarrhoea—Hydrocortisone—psoriasis	5.85e-05	0.000193	CcSEcCtD
Propafenone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.84e-05	0.00361	CbGpPWpGaD
Propafenone—Leukopenia—Methotrexate—psoriasis	5.83e-05	0.000192	CcSEcCtD
Propafenone—Urticaria—Dexamethasone—psoriasis	5.81e-05	0.000191	CcSEcCtD
Propafenone—Urticaria—Betamethasone—psoriasis	5.81e-05	0.000191	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Prednisone—psoriasis	5.8e-05	0.000191	CcSEcCtD
Propafenone—Dizziness—Prednisolone—psoriasis	5.79e-05	0.000191	CcSEcCtD
Propafenone—Asthenia—Triamcinolone—psoriasis	5.78e-05	0.000191	CcSEcCtD
Propafenone—Abdominal pain—Dexamethasone—psoriasis	5.78e-05	0.000191	CcSEcCtD
Propafenone—Abdominal pain—Betamethasone—psoriasis	5.78e-05	0.000191	CcSEcCtD
Propafenone—Body temperature increased—Dexamethasone—psoriasis	5.78e-05	0.000191	CcSEcCtD
Propafenone—Body temperature increased—Betamethasone—psoriasis	5.78e-05	0.000191	CcSEcCtD
Propafenone—Insomnia—Prednisone—psoriasis	5.76e-05	0.00019	CcSEcCtD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	5.75e-05	0.00355	CbGpPWpGaD
Propafenone—Nausea—Cyclosporine—psoriasis	5.72e-05	0.000189	CcSEcCtD
Propafenone—Paraesthesia—Prednisone—psoriasis	5.71e-05	0.000188	CcSEcCtD
Propafenone—Pruritus—Triamcinolone—psoriasis	5.7e-05	0.000188	CcSEcCtD
Propafenone—Cough—Methotrexate—psoriasis	5.69e-05	0.000188	CcSEcCtD
Propafenone—Dizziness—Hydrocortisone—psoriasis	5.66e-05	0.000187	CcSEcCtD
Propafenone—Convulsion—Methotrexate—psoriasis	5.65e-05	0.000186	CcSEcCtD
Propafenone—Dyspepsia—Prednisone—psoriasis	5.6e-05	0.000185	CcSEcCtD
Propafenone—ADRB1—GPCR downstream signaling—HCAR2—psoriasis	5.58e-05	0.00344	CbGpPWpGaD
Propafenone—Nausea—Mycophenolate mofetil—psoriasis	5.58e-05	0.000184	CcSEcCtD
Propafenone—Myalgia—Methotrexate—psoriasis	5.55e-05	0.000183	CcSEcCtD
Propafenone—Chest pain—Methotrexate—psoriasis	5.55e-05	0.000183	CcSEcCtD
Propafenone—Decreased appetite—Prednisone—psoriasis	5.53e-05	0.000182	CcSEcCtD
Propafenone—Rash—Prednisolone—psoriasis	5.52e-05	0.000182	CcSEcCtD
Propafenone—Dermatitis—Prednisolone—psoriasis	5.52e-05	0.000182	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.51e-05	0.000182	CcSEcCtD
Propafenone—Fatigue—Prednisone—psoriasis	5.49e-05	0.000181	CcSEcCtD
Propafenone—Headache—Prednisolone—psoriasis	5.49e-05	0.000181	CcSEcCtD
Propafenone—Discomfort—Methotrexate—psoriasis	5.48e-05	0.000181	CcSEcCtD
Propafenone—Constipation—Prednisone—psoriasis	5.44e-05	0.000179	CcSEcCtD
Propafenone—Vomiting—Hydrocortisone—psoriasis	5.44e-05	0.000179	CcSEcCtD
Propafenone—Rash—Hydrocortisone—psoriasis	5.39e-05	0.000178	CcSEcCtD
Propafenone—Dermatitis—Hydrocortisone—psoriasis	5.39e-05	0.000178	CcSEcCtD
Propafenone—Confusional state—Methotrexate—psoriasis	5.36e-05	0.000177	CcSEcCtD
Propafenone—Headache—Hydrocortisone—psoriasis	5.36e-05	0.000177	CcSEcCtD
Propafenone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	5.35e-05	0.0033	CbGpPWpGaD
Propafenone—Dizziness—Triamcinolone—psoriasis	5.33e-05	0.000176	CcSEcCtD
Propafenone—Infection—Methotrexate—psoriasis	5.28e-05	0.000174	CcSEcCtD
Propafenone—Feeling abnormal—Prednisone—psoriasis	5.24e-05	0.000173	CcSEcCtD
Propafenone—Asthenia—Betamethasone—psoriasis	5.24e-05	0.000173	CcSEcCtD
Propafenone—Asthenia—Dexamethasone—psoriasis	5.24e-05	0.000173	CcSEcCtD
Propafenone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.23e-05	0.00323	CbGpPWpGaD
Propafenone—Nervous system disorder—Methotrexate—psoriasis	5.22e-05	0.000172	CcSEcCtD
Propafenone—Thrombocytopenia—Methotrexate—psoriasis	5.21e-05	0.000172	CcSEcCtD
Propafenone—Gastrointestinal pain—Prednisone—psoriasis	5.2e-05	0.000172	CcSEcCtD
Propafenone—ABCB1—Allograft Rejection—IL10—psoriasis	5.2e-05	0.00321	CbGpPWpGaD
Propafenone—Nausea—Prednisolone—psoriasis	5.2e-05	0.000172	CcSEcCtD
Propafenone—Pruritus—Dexamethasone—psoriasis	5.17e-05	0.000171	CcSEcCtD
Propafenone—Pruritus—Betamethasone—psoriasis	5.17e-05	0.000171	CcSEcCtD
Propafenone—Skin disorder—Methotrexate—psoriasis	5.17e-05	0.00017	CcSEcCtD
Propafenone—Hyperhidrosis—Methotrexate—psoriasis	5.14e-05	0.00017	CcSEcCtD
Propafenone—ADRB1—GPCR ligand binding—CCL20—psoriasis	5.13e-05	0.00316	CbGpPWpGaD
Propafenone—Vomiting—Triamcinolone—psoriasis	5.12e-05	0.000169	CcSEcCtD
Propafenone—Nausea—Hydrocortisone—psoriasis	5.08e-05	0.000168	CcSEcCtD
Propafenone—Rash—Triamcinolone—psoriasis	5.08e-05	0.000167	CcSEcCtD
Propafenone—Dermatitis—Triamcinolone—psoriasis	5.07e-05	0.000167	CcSEcCtD
Propafenone—Anorexia—Methotrexate—psoriasis	5.07e-05	0.000167	CcSEcCtD
Propafenone—ADRB1—Signaling by GPCR—HCAR2—psoriasis	5.07e-05	0.00313	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—IL4—psoriasis	5.06e-05	0.00312	CbGpPWpGaD
Propafenone—Urticaria—Prednisone—psoriasis	5.06e-05	0.000167	CcSEcCtD
Propafenone—Headache—Triamcinolone—psoriasis	5.05e-05	0.000166	CcSEcCtD
Propafenone—Body temperature increased—Prednisone—psoriasis	5.03e-05	0.000166	CcSEcCtD
Propafenone—Abdominal pain—Prednisone—psoriasis	5.03e-05	0.000166	CcSEcCtD
Propafenone—Diarrhoea—Betamethasone—psoriasis	5e-05	0.000165	CcSEcCtD
Propafenone—Diarrhoea—Dexamethasone—psoriasis	5e-05	0.000165	CcSEcCtD
Propafenone—SCN5A—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.99e-05	0.00308	CbGpPWpGaD
Propafenone—Hypotension—Methotrexate—psoriasis	4.97e-05	0.000164	CcSEcCtD
Propafenone—ABCB1—Allograft Rejection—HLA-B—psoriasis	4.95e-05	0.00305	CbGpPWpGaD
Propafenone—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	4.94e-05	0.00305	CbGpPWpGaD
Propafenone—Musculoskeletal discomfort—Methotrexate—psoriasis	4.85e-05	0.00016	CcSEcCtD
Propafenone—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.84e-05	0.00299	CbGpPWpGaD
Propafenone—Dizziness—Betamethasone—psoriasis	4.83e-05	0.000159	CcSEcCtD
Propafenone—Dizziness—Dexamethasone—psoriasis	4.83e-05	0.000159	CcSEcCtD
Propafenone—Insomnia—Methotrexate—psoriasis	4.81e-05	0.000159	CcSEcCtD
Propafenone—Nausea—Triamcinolone—psoriasis	4.78e-05	0.000158	CcSEcCtD
Propafenone—Paraesthesia—Methotrexate—psoriasis	4.78e-05	0.000158	CcSEcCtD
Propafenone—Dyspnoea—Methotrexate—psoriasis	4.74e-05	0.000156	CcSEcCtD
Propafenone—Somnolence—Methotrexate—psoriasis	4.73e-05	0.000156	CcSEcCtD
Propafenone—Hypersensitivity—Prednisone—psoriasis	4.69e-05	0.000155	CcSEcCtD
Propafenone—Dyspepsia—Methotrexate—psoriasis	4.68e-05	0.000154	CcSEcCtD
Propafenone—Vomiting—Betamethasone—psoriasis	4.65e-05	0.000153	CcSEcCtD
Propafenone—Vomiting—Dexamethasone—psoriasis	4.65e-05	0.000153	CcSEcCtD
Propafenone—SCN5A—SIDS Susceptibility Pathways—JUN—psoriasis	4.64e-05	0.00287	CbGpPWpGaD
Propafenone—Decreased appetite—Methotrexate—psoriasis	4.62e-05	0.000152	CcSEcCtD
Propafenone—Rash—Betamethasone—psoriasis	4.61e-05	0.000152	CcSEcCtD
Propafenone—Rash—Dexamethasone—psoriasis	4.61e-05	0.000152	CcSEcCtD
Propafenone—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	4.61e-05	0.00284	CbGpPWpGaD
Propafenone—Dermatitis—Betamethasone—psoriasis	4.6e-05	0.000152	CcSEcCtD
Propafenone—Dermatitis—Dexamethasone—psoriasis	4.6e-05	0.000152	CcSEcCtD
Propafenone—Gastrointestinal disorder—Methotrexate—psoriasis	4.59e-05	0.000151	CcSEcCtD
Propafenone—Fatigue—Methotrexate—psoriasis	4.59e-05	0.000151	CcSEcCtD
Propafenone—ABCB1—Allograft Rejection—HLA-A—psoriasis	4.59e-05	0.00283	CbGpPWpGaD
Propafenone—Headache—Dexamethasone—psoriasis	4.58e-05	0.000151	CcSEcCtD
Propafenone—Headache—Betamethasone—psoriasis	4.58e-05	0.000151	CcSEcCtD
Propafenone—Asthenia—Prednisone—psoriasis	4.57e-05	0.000151	CcSEcCtD
Propafenone—Pain—Methotrexate—psoriasis	4.55e-05	0.00015	CcSEcCtD
Propafenone—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.53e-05	0.0028	CbGpPWpGaD
Propafenone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.51e-05	0.00278	CbGpPWpGaD
Propafenone—Pruritus—Prednisone—psoriasis	4.5e-05	0.000148	CcSEcCtD
Propafenone—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	4.5e-05	0.00278	CbGpPWpGaD
Propafenone—SCN5A—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.47e-05	0.00276	CbGpPWpGaD
Propafenone—Feeling abnormal—Methotrexate—psoriasis	4.38e-05	0.000145	CcSEcCtD
Propafenone—Diarrhoea—Prednisone—psoriasis	4.35e-05	0.000144	CcSEcCtD
Propafenone—Gastrointestinal pain—Methotrexate—psoriasis	4.35e-05	0.000143	CcSEcCtD
Propafenone—Nausea—Betamethasone—psoriasis	4.34e-05	0.000143	CcSEcCtD
Propafenone—Nausea—Dexamethasone—psoriasis	4.34e-05	0.000143	CcSEcCtD
Propafenone—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.33e-05	0.00267	CbGpPWpGaD
Propafenone—Urticaria—Methotrexate—psoriasis	4.23e-05	0.000139	CcSEcCtD
Propafenone—Dizziness—Prednisone—psoriasis	4.21e-05	0.000139	CcSEcCtD
Propafenone—Abdominal pain—Methotrexate—psoriasis	4.2e-05	0.000139	CcSEcCtD
Propafenone—Body temperature increased—Methotrexate—psoriasis	4.2e-05	0.000139	CcSEcCtD
Propafenone—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	4.19e-05	0.00258	CbGpPWpGaD
Propafenone—SCN5A—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.06e-05	0.0025	CbGpPWpGaD
Propafenone—Vomiting—Prednisone—psoriasis	4.05e-05	0.000133	CcSEcCtD
Propafenone—Rash—Prednisone—psoriasis	4.01e-05	0.000132	CcSEcCtD
Propafenone—Dermatitis—Prednisone—psoriasis	4.01e-05	0.000132	CcSEcCtD
Propafenone—Headache—Prednisone—psoriasis	3.99e-05	0.000131	CcSEcCtD
Propafenone—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.93e-05	0.00243	CbGpPWpGaD
Propafenone—Hypersensitivity—Methotrexate—psoriasis	3.92e-05	0.000129	CcSEcCtD
Propafenone—Asthenia—Methotrexate—psoriasis	3.82e-05	0.000126	CcSEcCtD
Propafenone—Nausea—Prednisone—psoriasis	3.78e-05	0.000125	CcSEcCtD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.76e-05	0.00232	CbGpPWpGaD
Propafenone—Pruritus—Methotrexate—psoriasis	3.76e-05	0.000124	CcSEcCtD
Propafenone—Diarrhoea—Methotrexate—psoriasis	3.64e-05	0.00012	CcSEcCtD
Propafenone—Dizziness—Methotrexate—psoriasis	3.52e-05	0.000116	CcSEcCtD
Propafenone—SCN5A—SIDS Susceptibility Pathways—TNF—psoriasis	3.48e-05	0.00215	CbGpPWpGaD
Propafenone—Vomiting—Methotrexate—psoriasis	3.38e-05	0.000112	CcSEcCtD
Propafenone—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	3.37e-05	0.00208	CbGpPWpGaD
Propafenone—Rash—Methotrexate—psoriasis	3.35e-05	0.000111	CcSEcCtD
Propafenone—Dermatitis—Methotrexate—psoriasis	3.35e-05	0.00011	CcSEcCtD
Propafenone—Headache—Methotrexate—psoriasis	3.33e-05	0.00011	CcSEcCtD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.25e-05	0.00201	CbGpPWpGaD
Propafenone—SCN5A—Axon guidance—TYK2—psoriasis	3.2e-05	0.00197	CbGpPWpGaD
Propafenone—Nausea—Methotrexate—psoriasis	3.16e-05	0.000104	CcSEcCtD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.13e-05	0.00193	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—IFNG—psoriasis	3.06e-05	0.00189	CbGpPWpGaD
Propafenone—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.05e-05	0.00188	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—HCAR2—psoriasis	2.99e-05	0.00185	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—LEP—psoriasis	2.99e-05	0.00184	CbGpPWpGaD
Propafenone—ADRB1—GPCR downstream signaling—CCL20—psoriasis	2.9e-05	0.00179	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.84e-05	0.00176	CbGpPWpGaD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.84e-05	0.00175	CbGpPWpGaD
Propafenone—SCN5A—SIDS Susceptibility Pathways—IL6—psoriasis	2.81e-05	0.00173	CbGpPWpGaD
Propafenone—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	2.72e-05	0.00168	CbGpPWpGaD
Propafenone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.67e-05	0.00165	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—CCL20—psoriasis	2.63e-05	0.00162	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—PPARG—psoriasis	2.6e-05	0.00161	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—TAGAP—psoriasis	2.6e-05	0.0016	CbGpPWpGaD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.44e-05	0.0015	CbGpPWpGaD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.44e-05	0.0015	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.34e-05	0.00145	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.31e-05	0.00143	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—TYK2—psoriasis	2.28e-05	0.00141	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—NDUFA5—psoriasis	2.27e-05	0.0014	CbGpPWpGaD
Propafenone—SCN5A—Axon guidance—VEGFA—psoriasis	2.26e-05	0.00139	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.12e-05	0.00131	CbGpPWpGaD
Propafenone—ABCB1—Allograft Rejection—TNF—psoriasis	1.98e-05	0.00122	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—NDUFA5—psoriasis	1.98e-05	0.00122	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.97e-05	0.00121	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—CYP2S1—psoriasis	1.93e-05	0.00119	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—NDUFA5—psoriasis	1.87e-05	0.00115	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—NDUFA5—psoriasis	1.85e-05	0.00114	CbGpPWpGaD
Propafenone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.84e-05	0.00114	CbGpPWpGaD
Propafenone—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.82e-05	0.00112	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—NFKB1—psoriasis	1.78e-05	0.0011	CbGpPWpGaD
Propafenone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.76e-05	0.00108	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.72e-05	0.00106	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—CYP2S1—psoriasis	1.68e-05	0.00104	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—VEGFA—psoriasis	1.61e-05	0.000995	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—STAT3—psoriasis	1.6e-05	0.000986	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—CYP2S1—psoriasis	1.59e-05	0.000979	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—NDUFA5—psoriasis	1.58e-05	0.000975	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—CYP2S1—psoriasis	1.57e-05	0.00097	CbGpPWpGaD
Propafenone—SCN5A—Axon guidance—IL6—psoriasis	1.56e-05	0.000965	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—CCL20—psoriasis	1.55e-05	0.000959	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.47e-05	0.000909	CbGpPWpGaD
Propafenone—ADRB1—GPCR ligand binding—CXCL8—psoriasis	1.39e-05	0.000855	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—TNF—psoriasis	1.38e-05	0.000853	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—CYP2S1—psoriasis	1.34e-05	0.000829	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.31e-05	0.000805	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.26e-05	0.000775	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.22e-05	0.000753	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.14e-05	0.000704	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—IL6—psoriasis	1.12e-05	0.000688	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.04e-05	0.00064	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.01e-05	0.000625	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	9.77e-06	0.000603	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—CARM1—psoriasis	9.44e-06	0.000582	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.82e-06	0.000544	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	8.61e-06	0.000532	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—SOCS1—psoriasis	8.56e-06	0.000528	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.24e-06	0.000508	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—CARM1—psoriasis	8.22e-06	0.000507	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—TYK2—psoriasis	8.16e-06	0.000504	CbGpPWpGaD
Propafenone—ADRB1—GPCR downstream signaling—CXCL8—psoriasis	7.83e-06	0.000483	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—CARM1—psoriasis	7.75e-06	0.000478	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—CARM1—psoriasis	7.68e-06	0.000474	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.18e-06	0.000443	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—CXCL8—psoriasis	7.11e-06	0.000439	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.04e-06	0.000435	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—CARM1—psoriasis	6.56e-06	0.000405	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—LEP—psoriasis	6.32e-06	0.00039	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—APOE—psoriasis	6.32e-06	0.00039	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.13e-06	0.000378	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—NFKBIA—psoriasis	5.89e-06	0.000363	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—CAT—psoriasis	5.8e-06	0.000358	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—CARM1—psoriasis	5.06e-06	0.000312	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—CAT—psoriasis	5.06e-06	0.000312	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—TYK2—psoriasis	4.82e-06	0.000298	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—CAT—psoriasis	4.76e-06	0.000294	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—CAT—psoriasis	4.72e-06	0.000291	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—APOE—psoriasis	4.51e-06	0.000278	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—CXCL8—psoriasis	4.2e-06	0.000259	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—CAT—psoriasis	4.04e-06	0.000249	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—IL6—psoriasis	3.99e-06	0.000246	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—APOE—psoriasis	3.93e-06	0.000242	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—PPARG—psoriasis	3.93e-06	0.000242	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—JUN—psoriasis	3.9e-06	0.000241	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—NFKB1—psoriasis	3.76e-06	0.000232	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—APOE—psoriasis	3.7e-06	0.000228	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—APOE—psoriasis	3.67e-06	0.000226	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—PPARG—psoriasis	3.42e-06	0.000211	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—VEGFA—psoriasis	3.41e-06	0.00021	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—STAT3—psoriasis	3.38e-06	0.000208	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—PPARG—psoriasis	3.22e-06	0.000199	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—PPARG—psoriasis	3.2e-06	0.000197	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—APOE—psoriasis	3.14e-06	0.000194	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—CAT—psoriasis	3.12e-06	0.000192	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—PPARG—psoriasis	2.73e-06	0.000169	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—TP53—psoriasis	2.58e-06	0.000159	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—APOE—psoriasis	2.42e-06	0.000149	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—IL6—psoriasis	2.36e-06	0.000146	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—PPARG—psoriasis	2.11e-06	0.00013	CbGpPWpGaD
